Merck Alzheimer's drug fails in 1 study; another continues

Tuesday, 14 February 2017
*By The Canadian Press*

KENILWORTH, N.J. — Merck & Co. will stop its study of an experimental Alzheimer's drug in people with mild or moderate symptoms because interim results showed "virtually no chance" of any benefit.

However, the drugmaker said Tuesday it will continue another study of the drug, verubecestat, in...

Related Videos

Wochit News -   ▶  00:35


Recent related news

(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Impax Laboratories Inc's generic version of Merck & Co's cholesterol-reducing drug...
2 days ago • Reuters
The Medicines Company (NASDAQ:MDCO) and partner Alnylam Pharmaceuticals Inc (LON:ALNY) have agreed details for a Phase III trial for heart disease drug...
2 days ago • Proactive Investors
Bristol Myers Squibb Co (NYSE:BMY) was set for a strong start as first quarter earnings beat forecasts on the back of booming sales of key cancer drug Opdivo and...
1 day ago • Proactive Investors
Eli Lilly & Co (NYSE:LLY) has reported improved survival rates in advanced breast cancer patients treated with a new drug combination. A higher survival rate was...
4 days ago • Proactive Investors

You might like